Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 238

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 238
---
, 2027.                                              

F-21
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 

5.         Acquisition       
     of Aeterna Zentaris Inc.
-----------------------------
 
As discussed in Note 1, Business Overview, as a result of the Transaction, Ceapro acquired control of Aeterna Zentaris Inc. on June 3, 2024. Aeterna is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Aeterna’s lead product, Macrilen® (macimorelin), is the first and only U.S. FDA and EMA approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macimorelin is currently marketed under the tradename Ghryvelin™ in the European Economic Area and the United Kingdom through an exclusive licensing agreement with Pharmanovia.
 
The Transaction was accounted for as a reverse acquisition under the acquisition method of accounting for business combinations. Ceapro was considered to be the accounting acquirer, and Aeterna was considered the legal acquirer. Under the acquisition method of accounting, total consideration exchanged and allocation of the purchase price to the fair values of assets acquired and liabilities assumed in the Transaction were as follows:
  Schedule of purchase price to the fair values of assets acquired and liabilities assumed
 Final Purchase Price Allocation
 

                                                                                  Number           Amount       
----------------------------------------------------------------------------------------------------------------
                                                                             #                                 $
Purchase price                                                                                                  
Shares deemed issued to Aeterna shareholders(1)                                    1,213,967           8,485    
Warrants issued to Aeterna shareholders(2)                                           633,543           4,422    
Replacement share-based payment awards:                                                                         
Equity-settled options(3)                                                             12,949               9    
Cash-settled DSUs(3)                                                                  49,230             344    
Warrants deemed issued(4)                                                            114,405               2    
                                                                                   2,024,094          13,262    
Recognized amounts of identifiable assets acquired and liabilities assumed                                      
Cash and cash equivalents                                                                             26,037    
Trade and other receivables                                                                              142    
Inventories                                                                                               64